4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Myelofibrosis Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Myelofibrosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 138 ongoing clinical trials involving Myelofibrosis
Of the 138 trials,60 trials are in Phase II
Furthermore, 31 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Myelofibrosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Myelofibrosis, an oncology indication. The largest number of ongoing clinical trials for Myelofibrosis is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Myelofibrosis-related drug trials.

Incyte Corp: The leading ongoing Myelofibrosis related clinical trial sponsor

University of Texas MD Anderson Cancer Center is the top sponsor for Myelofibrosis-related ongoing clinical trials.

AbbVie Inc, University of Texas MD Anderson Cancer Center, Celgene Corp, and City of Hope are among other notable clinical trial sponsors involved in Myelofibrosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Myelofibrosis

Ruxolitinib (INCB18424, Jakafi, Jakavi), Fedratinib (Inrebic, Fedratinib dihydrochloride) are among the key marketed drugs involving Myelofibrosis.

Ruxolitinib (INCB18424, Jakafi, Jakavi) is an anti-neoplastic, immunomodulating and anti-inflammatory agent. It functions via Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Inhibitor mechanism of action. It is formulated as tablet for oral administration. Ruxolitinib is marketed for the treatment of Myelofibrosis and several other indications including Coronavirus Disease 2019 (COVID-19), Myelofibrosis, Graft Versus Host Disease (GVHD), Polycythemia Vera, Splenomegaly, Thrombocythemia Myelofibrosis. Ruxolitinib was first approved in 2011 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several pharma giants including Novartis AG, and Incyte Corp.

Fedratinib (Inrebic, Fedratinib dihydrochloride) is an antineoplastic agent. It functions via Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Inhibitor; Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Inhibitor mechanism of action. It is formulated as hard gelatin capsules, hard capsules for oral route of administration. Fedratinib is marketed for the treatment of Myelofibrosis and several other indications including Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Splenomegaly. Fedratinib was first approved in 2019 and is marketed globally including the US, the UK, France, and Germany by Bristol-Myers Squibb Co and its subsidiaries.

Explore the latest trends and actionable insights on the Myelofibrosis Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Myelofibrosis Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store